hTERT mRNA expression in urine as a useful diagnostic tool in bladder cancer. Comparison with cytology and NMP22 BladderCheck Test®
Autor: | S. Aliño-Pellicer, M.J. Herrero-Cervera, José María Martínez-Jabaloyas, J.A. March-Villalba, Jorge Panach-Navarrete |
---|---|
Rok vydání: | 2018 |
Předmět: |
medicine.medical_specialty
Bladder cancer medicine.diagnostic_test business.industry Urinary system 030232 urology & nephrology Urology General Medicine Urine Cystoscopy medicine.disease law.invention 03 medical and health sciences Htert mrna 0302 clinical medicine Randomized controlled trial law 030220 oncology & carcinogenesis Cytology medicine Telomerase reverse transcriptase business |
Zdroj: | Actas Urológicas Españolas (English Edition). 42:524-530 |
ISSN: | 2173-5786 |
Popis: | Introduction To study the relationship between quantitative mRNA determination (hTERT) in patients with bladder tumor, history of bladder tumor, and in subjects without a history of this neoplasia. Material and methods A prospective randomized controlled study with 91 subjects included. The value of mRNA-hTERTN was determined in 63 patients with a history or suspicion of bladder tumor and in 28 controls. Urine samples were sent for evaluation of the mRNA level (hTERT), the cytological study and the NMP22 result. Results Differences were observed in mean hTERTN levels in each of the groups: tumor presence 21.33 ± 40.66, tumor history 2.16 ± 2.67, controls 0.9 ± 1.75 (p Conclusions hTERTN mRNA levels in urine were higher in patients with bladder tumors compared to patients with a history of bladder tumor and with negative cystoscopy, as well as in the control group. This determination showed a higher diagnostic yield compared with the detection of NMP22 and urinary cytology. |
Databáze: | OpenAIRE |
Externí odkaz: |